Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of the impact of Anti-IL5 neutralizing antibodies on bone marrow eosinophil maturation stages during IL-33 induced eosinophilia.

ABSTRACT: Study of the impact of Anti-IL5 neutralizing antibodies on bone marrow eosinophil maturation stages during IL-33 induced eosinophilia.

PROVIDER: PRJNA1045640 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26960600_1.fastq.gz	Fastqsanger.gz
	SRR26960600_2.fastq.gz	Fastqsanger.gz
	SRR26960601_1.fastq.gz	Fastqsanger.gz
	SRR26960601_2.fastq.gz	Fastqsanger.gz
	SRR26960602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

Study of the impact of Anti-IL5 neutralizing antibodies on bone marrow eosinophil maturation stages during IL-33 induced eosinophilia.

Project description:RNA-seq of the 4 eosinophil maturation stages in the murine bone marrow during Interleukin-33 induced eosinophilia combined with Anti-IL5 or Control isotype injections.

2024-05-21 | GSE248712 | GEO

Prediction of broadly neutralizing antibodies

Project description:Prediction of broadly neutralizing antibodies

| PRJNA952996 | ENA

Prediction of broadly neutralizing antibodies [Singleron]

Project description:Prediction of broadly neutralizing antibodies [Singleron]

| PRJNA952999 | ENA

Prediction of broadly neutralizing antibodies [10X]

Project description:Prediction of broadly neutralizing antibodies [10X]

| PRJNA952157 | ENA

A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer

Project description:A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer

| PRJNA883192 | ENA

Prediction of broadly neutralizing antibodies [BD Rhapsody]

Project description:Prediction of broadly neutralizing antibodies [BD Rhapsody]

| PRJNA952998 | ENA

Mouse Eosinophil

Project description:MicroRNA have been implicated in the differentiation and control of eosinophilia in allergic inflammation, however, a detailed investigation of miRNA expression patterns employed during differentiation has not yet been performed [35-37]. The aim of our study is to explore miRNA expression profiling and analysis in silico in order to improve our understanding of the factors and circuits that are involved in the regulation eosinophil growth and differentiation.

2014-08-01 | E-MTAB-2442 | biostudies-arrayexpress

Potent neutralizing antibodies against SARS-CoV-2

Project description:The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here we report the rapid identification of SARS-CoV-2 neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients.

| EGAS00001004412 | EGA

Neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic activity

Project description:SARS-CoV-2 has spread globally and caused the COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 are in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibodies (mAbs) in SARS-CoV-2-infected mice. Whereas Fc effector functions are fully dispensable when mAbs are administered as prophylaxis, they are required for optimal protection as therapy. When given after infection, intact but not LALA-PG loss of Fc effector function variant mAbs reduce SARS-CoV-2 burden and lung disease in mice and hamsters. Fc engagement of neutralizing antibodies mitigates inflammation and improves respiratory mechanics, and transcriptional profiling suggests these phenotypes are associated with diminished innate immune signaling and enhanced tissue repair. Immune cell depletions establish that neutralizing mAbs require monocytes for therapeutic efficacy. Our study demonstrates that therapeutic neutralizing mAbs require Fc effector functions to reduce SARS-CoV-2 infection and modulate protective immune responses.

2021-03-01 | GSE161615 | GEO

CHIKV VLP Vaccination in Humans induced broadly neutralizing antibodies

Project description:CHIKV VLP Vaccination in Humans induced broadly neutralizing antibodies

| PRJNA905836 | ENA